Singapore markets closed
Straits Times Index
3,338.94 -9.93 (-0.30%) S&P 500
5,283.40 +5.89 (+0.11%) Dow
38,571.03 -115.27 (-0.30%) Nasdaq
16,828.67 +93.67 (+0.56%) Bitcoin USD
68,880.01 -232.34 (-0.34%) CMC Crypto 200
1,441.47 -5.68 (-0.39%)
Protalix BioTherapeutics, Inc. (PLX)
NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 84.31M |
| Enterprise value | 62.20M |
| Trailing P/E | 14.38 |
| Forward P/E | 9.59 |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 1.66 |
| Price/book (mrq) | 2.83 |
| Enterprise value/revenue | 1.04 |
| Enterprise value/EBITDA | 5.69 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.90 |
| 52-week change 3 | -51.68% |
| S&P500 52-week change 3 | 23.33% |
| 52-week high 3 | 2.5100 |
| 52-week low 3 | 1.0300 |
| 50-day moving average 3 | 1.1874 |
| 200-day moving average 3 | 1.4923 |
Share statistics
| Avg vol (3-month) 3 | 429.98k |
| Avg vol (10-day) 3 | 397.71k |
| Shares outstanding 5 | 73.32M |
| Implied shares outstanding 6 | 73.32M |
| Float 8 | 54.52M |
| % held by insiders 1 | 14.58% |
| % held by institutions 1 | 13.00% |
| Shares short (15 May 2024) 4 | 6.26M |
| Short ratio (15 May 2024) 4 | 12.82 |
| Short % of float (15 May 2024) 4 | 8.93% |
| Short % of shares outstanding (15 May 2024) 4 | 8.54% |
| Shares short (prior month 15 Apr 2024) 4 | 6.7M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | 20 Dec 2019 |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:10 |
| Last split date 3 | 20 Dec 2019 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | 11.48% |
| Operating margin (ttm) | -129.56% |
Management effectiveness
| Return on assets (ttm) | 6.45% |
| Return on equity (ttm) | 44.48% |
Income statement
| Revenue (ttm) | 59.65M |
| Revenue per share (ttm) | 0.83 |
| Quarterly revenue growth (yoy) | -60.90% |
| Gross profit (ttm) | N/A |
| EBITDA | 9.3M |
| Net income avi to common (ttm) | 6.85M |
| Diluted EPS (ttm) | 0.0800 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 48.49M |
| Total cash per share (mrq) | 0.66 |
| Total debt (mrq) | 26.37M |
| Total debt/equity (mrq) | 88.54% |
| Current ratio (mrq) | 1.38 |
| Book value per share (mrq) | 0.41 |
Cash flow statement
| Operating cash flow (ttm) | 5.87M |
| Levered free cash flow (ttm) | 5.05M |
© 2024 Yahoo. All rights reserved.